5/31/2013 7:02:45 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Dendreon Corporation (NASDAQ: DNDN) announced today that four abstracts featuring PROVENGE® (sipuleucel-T) data from ongoing Phase II sequencing studies and the PROCEED registry, and two abstracts highlighting preliminary Phase II data of DN24-02, an investigational active cellular immunotherapy in patients with surgically resected HER2+ urothelial cancer, will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) from May 31-June 4, 2013 in Chicago, IL.
Help employers find you! Check out all the jobs and post your resume.
comments powered by